epocrates logo
epocrates logo
epocrates logo
  • 0

Diseases

Evaluation of hyperprolactinemia

OVERVIEW

  • Summary
  • Urgent Considerations
  • Etiology

DIAGNOSIS

  • Differential Diagnosis
  • Diagnostic Approach

IMAGES

  • Library

REFERENCES

  • Citations
  • Credits

Summary

AAFont SizeShareMore Information
Hyperprolactinemia is a condition of elevated serum prolactin (PRL). The level of PRL considered normal varies depending on the reference laboratory and type of immunoassay used, but it is commonly considered to be around <25 micrograms/L (<500 milliunits/L) in women and <20 micrograms/L (<400 milliunits/L) in men.[1] [2] [3]
Epidemiology
Hyperprolactinemia is the most common endocrine disorder of the hypothalamus-pituitary axis. The prevalence of hyperprolactinemia ranges from 0.4% in an unselected normal adult population to 26.8% in women and 2.1% in men undergoing fertility treatment.[4] [5]​​ It increases to 9% in women with amenorrhea and occurs in 25% of those with galactorrhea. Among women presenting with concomitant amenorrhea and galactorrhea, 70% are hyperprolactinemic. The condition also accounts for 5% of men who present with impotence or infertility.[2] [3]​​​ Although uncommon, hyperprolactinemia can also present in children.
Pathophysiology
The hormone PRL is a 199-amino acid peptide synthesized and secreted by lactotroph cells in the anterior pituitary gland; 80% of circulating PRL exists as a 23 kilodalton (kD) monomer.[6]​ Dimeric PRL (also known as big PRL) has a molecular weight of 50 kD to 60 kD and accounts for 10% to 15%; the remainder is macroprolactin (also known as big-big PRL), a high molecular weight (>150 kD) complex of monomeric PRL and IgG.[7] [8] PRL is also produced by numerous extrapituitary tissues, including various brain regions, lymphocytes, mammary epithelial cells, and tumors, as well as the decidua, myometrium, lacrimal gland, thymus, and spleen.[9] Although it derives from an ancestral hormone common to growth hormone and human placental lactogen, PRL displays little structural homology with these hormones.[7]
The main action of PRL is to stimulate breast epithelial cell proliferation and induce milk production. In addition to its lactogenic role, PRL promotes the formation and action of the corpus luteum and suppresses the pulsatile secretion of gonadotropin-releasing hormone (GnRH). Suppression of GnRH by PRL results in decreased levels of follicle-stimulating hormone and luteinizing hormone.[9] Moreover, PRL plays a direct inhibitory role in spermatogenesis and steroidogenesis, as its receptors have been detected in Sertoli and Leydig cells in the testes.[10]
PRL secretion is pulsatile and controlled predominantly by the inhibitory effect of dopamine released from the hypothalamus. Dopamine acts through its D2 receptors on lactotroph cells.[11]​ Other inhibitory factors are endothelin peptides, tumor growth factor-beta 1, and calcitonin.[12] [13] [14] Estrogens stimulate the proliferation of lactotroph cells, resulting in an increased quantity of these cells in premenopausal women, especially during pregnancy. PRL production is also stimulated by thyrotropin-releasing hormone, vasoactive intestinal peptide, and oxytocin.[7]
content by BMJ Group
Last updated

Library

  • MRI showing macroprolactinoma

    MRI showing macroprolactinoma

  • ​The investigation of hyperprolactinemia. TSH = thyroid-stimulating hormone; UE = urea and electroly

    ​The investigation of hyperprolactinemia. TSH = thyroid-stimulating hormone; UE = urea and electrolytes; LFT = liver function tests

Citations

    Key Articles

    • Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002 Nov;20(4):365-74.[Abstract]

    • Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf). 2005 Jun;62(6):633-43.[Abstract][Full Text]

    • Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement. Nat Rev Endocrinol. 2023 Dec;19(12):722-40.[Abstract][Full Text]

    • Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.[Abstract][Full Text]

    • Expert Panel on Neurologic Imaging; Burns J, Policeni B, et al. ACR appropriateness criteria(®) neuroendocrine imaging. J Am Coll Radiol. 2019 May;16(5s):S161-73.[Abstract][Full Text]

    Referenced Articles

    • 1. Leca BM, Mytilinaiou M, Tsoli M, et al. Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis. Sci Rep. 2021 May 7;11(1):9801.[Abstract][Full Text]

    • 2. Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ. 2003 Sep 16;169(6):575-81.[Abstract][Full Text]

    • 3. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002 Nov;20(4):365-74.[Abstract]

    • 4. Wojcik M, Amer S, Jayaprakasan K. The prevalence of hyperprolactinaemia in subfertile ovulatory women and its impact on fertility treatment outcome. J Obstet Gynaecol. 2022 Aug;42(6):2349-53.[Abstract]

    • 5. Ambulkar SS, Darves-Bornoz AL, Fantus RJ, et al. Prevalence of hyperprolactinemia and clinically apparent prolactinomas in men undergoing fertility evaluation. Urology. 2022 Jan;159:114-9.[Abstract]

    • 6. Vilar L, Abucham J, Albuquerque JL, et al. Controversial issues in the management of hyperprolactinemia and prolactinomas - an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018 Mar-Apr;62(2):236-63.[Abstract][Full Text]

    • 7. Ben-Jonathan N, LaPensee CR, LaPensee EW. What can we learn from rodents about prolactin in humans? Endocr Rev. 2008 Feb;29(1):1-41.[Abstract][Full Text]

    • 8. Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf). 2005 Jun;62(6):633-43.[Abstract][Full Text]

    • 9. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998 Jun;19(3):225-68.[Abstract][Full Text]

    • 10. Arowojolu AO, Akinloye O, Shittu OB. Serum and seminal plasma prolactin levels in male attenders of an infertility clinic in Ibadan. J Obstet Gynaecol. 2004 Apr;24(3):306-9.[Abstract]

    • 11. Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement. Nat Rev Endocrinol. 2023 Dec;19(12):722-40.[Abstract][Full Text]

    • 12. Kanyicska B, Lerant A, Freeman ME. Endothelin is an autocrine regulator of prolactin secretion. Endocrinology. 1998 Dec;139(12):5164-73.[Abstract][Full Text]

    • 13. Sarkar DK, Kim KH, Minami S. Transforming growth factor-beta 1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. Mol Endocrinol. 1992 Nov;6(11):1825-33.[Abstract]

    • 14. Shah GV, Pedchenko V, Stanley S, et al. Calcitonin is a physiological inhibitor of prolactin secretion in ovariectomized female rats. Endocrinology. 1996 May;137(5):1814-22.[Abstract]

    • 15. Vilar L, Freitas MC, Naves LA, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 2008 May;31(5):436-44.[Abstract]

    • 16. Schlechte JA. Long-term management of prolactinomas. J Clin Endocrinol Metab. 2007 Aug;92(8):2861-5.[Abstract][Full Text]

    • 17. Varaldo E, Cuboni D, Prencipe N, et al. Are prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia? Endocrine. 2024 May;84(2):670-6.[Abstract][Full Text]

    • 18. Kasantikul V, Shuangshoti S. Pituitary adenomas: immunohistochemical: study of 90 cases. J Med Assoc Thai. 1990 Sep;73(9):514-21.[Abstract]

    • 19. Korbonits M, Blair JC, Boguslawska A, et al. Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: part 2, specific diseases. Nat Rev Endocrinol. 2024 May;20(5):290-309.[Abstract][Full Text]

    • 20. Bonert VS, Melmed S. Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab. 2006 Jul;2(7):408-12.[Abstract]

    • 21. Beressi N, Beressi JP, Cohen R, et al. Lymphocytic hypophysitis. A review of 145 cases. Ann Med Interne (Paris). 1999 Jun;150(4):327-41.[Abstract]

    • 22. Bhardwaj M, Sharma A, Pal HK. Granulomatous hypophysitis. Neurol India. 2005 Sep;53(3):364-5.[Abstract][Full Text]

    • 23. Cortet-Rudelli C, Sapin R, Bonneville JF, et al. Etiological diagnosis of hyperprolactinemia. Ann Endocrinol (Paris). 2007 Jun;68(2-3):98-105.[Abstract]

    • 24. Goel P, Kahkasha, Narang S, et al. Evaluation of serum prolactin level in patients of subclinical and overt hypothyroidism. J Clin Diagn Res. 2015 Jan;9(1):BC15-7.[Abstract][Full Text]

    • 25. Kyritsi EM, Dimitriadis GK, Angelousi A, et al. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome. Eur J Clin Invest. 2018 Jul;48(7):e12961.[Abstract]

    • 26. Davoudi Z, Araghi F, Vahedi M, et al. Prolactin Level in Polycystic Ovary Syndrome (PCOS): an approach to the diagnosis and management. Acta Biomed. 2021 Nov 3;92(5):e2021291.[Abstract][Full Text]

    • 27. Saha MT, Saha HH, Niskanen LK, et al. Time course of serum prolactin and sex hormones following successful renal transplantation. Nephron. 2002;92(3):735-7.[Abstract]

    • 28. Pluguez-Turull CW, Nanyes JE, Quintero CJ, et al. Idiopathic granulomatous mastitis: manifestations at multimodality imaging and pitfalls. Radiographics. 2018 Mar-Apr;38(2):330-56.[Abstract]

    • 29. Kallenberg GA, Pesce CM, Norman B, et al. Ectopic hyperprolactinemia resulting from an ovarian teratoma. JAMA. 1990 May 9;263(18):2472-4.[Abstract]

    • 30. Korytnaya E, Liu J, Camelo-Piragua S, et al. Ectopic prolactin secretion from a perivascular epithelioid cell tumor (PEComa). J Clin Endocrinol Metab. 2014 Nov;99(11):3960-4.[Abstract]

    • 31. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-314.[Abstract]

    • 32. Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014 May;28(5):421-53.[Abstract][Full Text]

    • 33. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005 Aug;80(8):1050-7.[Abstract][Full Text]

    • 34. Teoh SK, Lex BW, Mendelson JH, et al. Hyperprolactinemia and macrocytosis in women with alcohol and polysubstance dependence. J Stud Alcohol. 1992 Mar;53(2):176-82.[Abstract]

    • 35. Coker F, Taylor D. Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management. CNS Drugs. 2010 Jul;24(7):563-74.[Abstract]

    • 36. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics: a review. Hum Psychopharmacol. 2010 Jun-Jul;25(4):281-97.[Abstract]

    • 37. Sarkar DK. Hyperprolactinemia following chronic alcohol administration. Front Horm Res. 2010;38:32-41.[Abstract]

    • 38. Che Soh NAA, Yaacob NM, Omar J, et al. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis. Int J Environ Res Public Health. 2020 Nov 6;17(21):8199.[Abstract][Full Text]

    • 39. Kasum M, Orešković S, Čehić E, et al. Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. Taiwan J Obstet Gynecol. 2017 Dec;56(6):719-24.[Abstract][Full Text]

    • 40. De Schepper J, Schiettecatte J, Velkeniers B, et al. Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexes. Eur J Endocrinol. 2003 Sep;149(3):201-7.[Abstract][Full Text]

    • 41. Leanos A, Pascoe D, Fraga A, et al. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus. 1998;7(6):398-403.[Abstract]

    • 42. Vallette-Kasic S, Morange-Ramos I, Selim A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab. 2002 Feb;87(2):581-8.[Abstract][Full Text]

    • 43. Saleem M, Martin H, Coates P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin Biochem Rev. 2018 Feb;39(1):3-16.[Abstract][Full Text]

    • 44. Hattori N, Ishihara T, Ikekubo K, et al. Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1992 Nov;75(5):1226-9.[Abstract]

    • 45. Hattori N, Ikekubo K, Ishihara T, et al. Effects of anti-prolactin autoantibodies on serum prolactin measurements. Eur J Endocrinol. 1994 May;130(5):434-7.[Abstract]

    • 46. Sachdev Y, Gopal K, Garg VK, et al. Pituitary apoplexy (spontaneous pituitary necrosis). Postgrad Med J. 1981 May;57(667):289-93.[Abstract][Full Text]

    • 47. Serhal D, Weil RJ, Hamrahian AH. Evaluation and management of pituitary incidentalomas. Cleve Clin J Med. 2008 Nov;75(11):793-801.[Abstract]

    • 48. Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):542-5.[Abstract][Full Text]

    • 49. Maccagnan P, Macedo CL, Kayath MJ, et al. Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab. 1995 Jul;80(7):2190-7.[Abstract]

    • 50. Nawar RN, AbdelMannan D, Selman WR, et al. Pituitary tumor apoplexy: a review. J Intensive Care Med. 2008 Mar-Apr;23(2):75-90.[Abstract]

    • 51. Auriemma RS, Pirchio R, Pivonello C, et al. Approach to the patient with prolactinoma. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-23.[Abstract][Full Text]

    • 52. Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.[Abstract][Full Text]

    • 53. Rusgis MM, Alabbasi AY, Nelson LA. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am J Health Syst Pharm. 2021 May 6;78(10):862-71.[Abstract][Full Text]

    • 54. Hammer F, Arlt W. Hypopituitarism [in German]. Internist (Berl). 2004 Jul;45(7):795-811.[Abstract]

    • 55. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980 Dec 25;303(26):1511-4.[Abstract]

    • 56. Biller BM. Hyperprolactinemia. Int J Fertil Womens Med. 1999 Mar-Apr;44(2):74-7.[Abstract]

    • 57. Fideleff HL, Boquete HR, Sequera A, et al. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab. 2000 Mar;13(3):261-7.[Abstract]

    • 58. Serri O, Li L, Mamputu JC, et al. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006 Apr;64(4):366-70.[Abstract]

    • 59. Arslan MS, Topaloglu O, Sahin M, et al. Preclinical atherosclerosis in patients with prolactinoma. Endocr Pract. 2014 May;20(5):447-51.[Abstract]

    • 60. Wagner R, Heni M, Linder K, et al. Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans. Acta Diabetol. 2014 Feb;51(1):71-8.[Abstract]

    • 61. Whyte MB, Pramodh S, Srikugan L, et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary. 2015 Jun;18(3):319-25.[Abstract]

    • 62. Sabogal Piñeros YS, Deckers MML, de Bie P, et al. Confusion in the interpretation of prolactin levels caused by inappropriately low reference intervals. Endocr Connect. 2024 Nov 21;13(12):e240432.[Abstract][Full Text]

    • 63. Beda-Maluga K, Pisarek H, Komorowski J, et al. Evaluation of hyperprolactinaemia with the use of the intervals for prolactin after macroforms separation. J Physiol Pharmacol. 2014 Jun;65(3):359-64.[Abstract][Full Text]

    • 64. Expert Panel on Neurologic Imaging; Burns J, Policeni B, et al. ACR appropriateness criteria(®) neuroendocrine imaging. J Am Coll Radiol. 2019 May;16(5s):S161-73.[Abstract][Full Text]

    • 65. Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med. 1994 May 15;120(10):817-20.[Abstract]

    • 66. Rand T, Kink E, Sator M, et al. MRI of microadenomas in patients with hyperprolactinaemia. Neuroradiology. 1996 Nov;38(8):744-6.[Abstract]

    • 67. Biller BM, Luciano A, Crosignani PG, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.[Abstract]

    • 68. Glezer A, Mendes Garmes H, Kasuki L, et al. Diagnosis of hyperprolactinemia in women: a position statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Arch Endocrinol Metab. 2024 Apr 5;68:e230502.[Abstract][Full Text]

    • 69. Karavitaki N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf). 2006 Oct;65(4):524-9.[Abstract]

    • 70. Kawaguchi T, Ogawa Y, Tominaga T. Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging. BMC Res Notes. 2014 Aug 20;7:555.[Abstract][Full Text]

    • 71. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000 Feb;85(2):526-9.[Abstract][Full Text]

    • 72. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447-69.[Abstract][Full Text]

    • 73. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf). 1999 Jul;51(1):119-26.[Abstract]

Have feedback?
Tell us about your experience
Scroll to Top
epocrates logo

Sign in to access our clinical decision support tools

Sign inCreate Account
Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information